Healthcare / BiotechnologyNasdaqCM
$6.34
+0.15 (+2.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-8.8M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$138M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.1%
↓Gross Margin
81.3%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-202.3%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.2M · net income $-20.7M · FCF $-20.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.2M | $10.2M | — | — | — |
| Net Income | $-20.7M | $-20.7M | $-14.8M | $-13.8M | $-12.1M |
| EBITDA | $-22.5M | $-22.5M | $-11.5M | $-13.6M | $-11.9M |
| EPS | -1.18 | -1.18 | -2.04 | -3.84 | -4.50 |
| Gross Margin | 81.3% | 81.3% | — | — | — |
| Operating Margin | -220.9% | -220.9% | — | — | — |
| Net Margin | -202.2% | -202.2% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.02 | -0.26 | -0.92 |
| Current Ratio | 12.64 | 12.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-20.7M | $-20.7M | $-7.8M | $-8.8M | $-9.2M |
| Returns | |||||
| ROE | -33.1% | -33.1% | -37.8% | 292.6% | 917.7% |
| Valuation | |||||
| P/B | 1.79 | 1.79 | 1.05 | — | — |
| Growth & Yield | |||||
| EPS Growth | 42.2% | 42.2% | 46.9% | 14.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.04 → -1.18
Residual
-32.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.